Limits...
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

MacDonald TM, Williams B, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Mackenzie IS, Salsbury J, Morant S, Ford I, Brown MJ - BMJ Open (2015)

Bottom Line: Hierarchical primary end points are: a comparison of home BP (home systolic blood pressure (HSBP)) averaged over the duration of phase 1 and 2 in the combination versus monotherapy arms.A sample size of 536 (268 in each group) will have 90% power to detect a difference in means of 4 mm Hg.PATHWAY 1 was approved by UK ethics (REC Reference 09/H0308/132).

View Article: PubMed Central - PubMed

Affiliation: Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.

No MeSH data available.


Related in: MedlinePlus

Study schematic.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4539389&req=5

BMJOPEN2015007645F1: Study schematic.

Mentions: The study is a prospective, multicentre, active-controlled, three-phase trial in UK patients with essential hypertension. A study schematic is shown in figure 1.


Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

MacDonald TM, Williams B, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Mackenzie IS, Salsbury J, Morant S, Ford I, Brown MJ - BMJ Open (2015)

Study schematic.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4539389&req=5

BMJOPEN2015007645F1: Study schematic.
Mentions: The study is a prospective, multicentre, active-controlled, three-phase trial in UK patients with essential hypertension. A study schematic is shown in figure 1.

Bottom Line: Hierarchical primary end points are: a comparison of home BP (home systolic blood pressure (HSBP)) averaged over the duration of phase 1 and 2 in the combination versus monotherapy arms.A sample size of 536 (268 in each group) will have 90% power to detect a difference in means of 4 mm Hg.PATHWAY 1 was approved by UK ethics (REC Reference 09/H0308/132).

View Article: PubMed Central - PubMed

Affiliation: Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.

No MeSH data available.


Related in: MedlinePlus